3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 3
2
Phase NA
1
Phase 1/2
1
Status
Completed
14
Terminated
6
Unknown
2
Recruiting
2
Active not recruiting
2
Withdrawn
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
24
Carcinoma, Non-Small-Cell Lung
20
Neoplasms
19
Colorectal Neoplasms
19
Recurrence
17
Pancreatic Neoplasms
17
Multiple Myeloma
15
Advanced Solid Tumors
13
Prostatic Neoplasms
12
Advanced Solid Tumor
12
Stomach Neoplasms
10
Ovarian Neoplasms
10
Leukemia, Myeloid, Acute
10
Carcinoma, Hepatocellular
10
Triple Negative Breast Neoplasms
8
Neoplasm Metastasis
7
Melanoma
7
Squamous Cell Carcinoma of Head and Neck
6
Small Cell Lung Carcinoma
6
Lymphoma, Large B-Cell, Diffuse
6
Head and Neck Neoplasms
6
Glioblastoma
6
Urinary Bladder Neoplasms
5
Solid Tumors
5
Solid Tumor
5
Lymphoma, B-Cell
5
Lung Neoplasms
5
Liver Neoplasms
5
Glioma
5
Endometrial Neoplasms
5
Interventions
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Not yet recruiting
×
Lymphoma, Extranodal NK-T-Cell
×
Clear all
NCT07502768
2026-03-31
EpiRev-NKT
Fudan University
Phase 1/2
Not yet recruiting
107 enrolled